Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin

INTRODUCTION: Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Using a crossover design, the present study compared trough levels of DPP-4 inhibition provided by these agents in a single cohort of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatosian, Daniel A., Guo, Ying, Schaeffer, Andrea K., Gaibu, Natalia, Popa, Serghei, Stoch, Aubrey, Langdon, Ronald B., Kauh, Eunkyung A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889317/
https://www.ncbi.nlm.nih.gov/pubmed/24163113
http://dx.doi.org/10.1007/s13300-013-0045-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889317/
https://www.ncbi.nlm.nih.gov/pubmed/24163113
http://dx.doi.org/10.1007/s13300-013-0045-8

Ejemplares similares